Status:
RECRUITING
Effects of COPD Standardized Management on COPD Exacerbation
Lead Sponsor:
China-Japan Friendship Hospital
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
This is a multi-center, parallel-group,cluster randomised trial involving secondary hospitals across China. The objective is to evaluate the effect of COPD on reducing moderate-to-severe exacerbations...
Detailed Description
COPD is the most common chronic respiratory disease in China. An effective and standardized condition management strategy is urgently needed to prevent acute exacerbation, improve the quality of life,...
Eligibility Criteria
Inclusion
- Aged ≥40 years
- Post-bronchodilator FEV1/FVC \<70%
- Baseline CAT score ≥10 or history of exacerbation in previous 12 months, defined as any use of oral antibiotics and/or oral or nebulized corticosteroids for increased cough, sputum and dyspnea, or exacerbation requiring hospitalization/ emergency admission.
- Local residents who live nearby and can be followed up throughout study period
- Written informed consent
Exclusion
- Pregnancy, breastfeeding, or potential pregnancy
- Primary diagnosis of asthma
- Having severe cognitive dysfunction
- Severely ill with less than 12-month life expectancy
- Patients with alcohol abuse history are excluded as alcoholic individuals may have low adherence to the study. Alcohol abuse is defined as an average alcohol intake \>80 g per day within recent two weeks, or daily intake of ≥40 g alcohol in men, and ≥20 g alcohol in women for more than 5 years.
- Have participated in similar trials or are undergoing other clinical trials
- Refuses or unable to give informed consent
- Plan to move
- Contraindicated to maintenance medicine.
- Unstable cardiovascular conditions (e.g., angina, myocardial infarction, ascending aortic aneurysm) that may prevent patients performing spirometry.
- Relative contraindications to spirometry, including current pneumothorax or planning to undergo thoracic/abdominal, ophthalmic or brain surgeries within next 6 months.
- Comorbid lung disease including bronchiectasis and tuberculosis, or undergoing anti-tuberculosis treatment
- Recent exacerbation treated with antibiotics and/or oral or nebulized corticosteroids within 30 days prior to enrolment.
- Exacerbation requiring emergency admission or hospitalization within 30 days prior to enrolment.
Key Trial Info
Start Date :
February 4 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
3456 Patients enrolled
Trial Details
Trial ID
NCT04664491
Start Date
February 4 2023
End Date
April 1 2027
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China, 100029